Meeting Demand for Biologics Development & Manufacturing

Scroll Down

With the recent tendency of drug developers to outsource their formulation development services, many CDMOs have adapted to this increased demand by providing innovative biologics development and manufacturing offerings in order to address the multitude of challenges that have arisen.

In this article, Genezen details its plan to build a new cGMP-compliant lentiviral vector production facility as part of a more expansive plan to build a larger 75,000 sq. ft site. The site will include multiple cGMP production suites as well as a full suite of process development capabilities to support cGMP and commercial readiness, which is elaborated upon within the article.

Read the full article here.

 

You may also be interested in...

Genezen completes cGMP-lentiviral and retroviral vector…

Genezen, a cell and gene therapy Contract Development and Manufacturing Organization...

Read more

Genezen announces launch of Scientific Advisory…

Leading experts in cell and gene therapy will provide guidance to...

Read more

Overcoming development and manufacturing challenges with…

As efficient and effective tools for gene transduction and delivering genes...

Read more

Retroviruses in CAR-T therapies: From gamma…

Introduction In recent years, chimeric antigen receptor T (CAR-T) cells have...

Read more